LSZ102X
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $983,241 | 6 | 0 |
| 2019 | $2.1M | 9 | 0 |
| 2018 | $939,087 | 7 | 1 |
| 2017 | $527,962 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.5M | 26 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I AND OR IB OPEN LABEL STUDY OF LSZ102 SINGLE AGENT AND LSZ102 IN COMBINATION WITH EITHER LEE011 LSZ102 PLUS LEE011 OR BYL719 LSZ102 PLUS BYL719 IN PATIENTS WITH ADVANCED OR METASTATIC ER PLUS BREAST CANCER WHO HAVE PROGRESSED AFTER ENDOCRINE THER | Novartis Pharmaceuticals Corporation | $3.3M | 0 |
| A PHASE I AND OR IB OPEN LABEL STUDY OF LSZ102 SINGLE AGENT AND LSZ102 IN COMBINATION WITH EITHER LEE011 LSZ102 PLUS LEE011 OR BYL719 LSZ102 PLUS BYL719 IN PATIENTS WITH ADVANCED OR METASTATIC ER PLUS BREAST CANCER WHO HAVE PROGRESSED AFTER ENDOCRINE THERAPY | Novartis Pharmaceuticals Corporation | $1.1M | 0 |
| A PHASE I AND OR IB OPEN LABEL STUDY OF LSZ102 SINGLE AGENT AND LSZ102 IN COMBINATION WITH EITHER LEE011 LSZ102 PLUS LEE011 OR BYL719 LSZ102 PLUS BYL719 IN PATIENTS WITH ADVANCED OR METASTATIC ER PLUS BREAST CANCER WHO HAVE PROGRESSED AFTER ENDOCRINE THER | NOVARTIS PHARMACEUTICALS CORPORATION | $124,984 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $558.58 | 1 |
Top Doctors Receiving Payments for LSZ102X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $4.5M | 25 |
| Komal Jhaveri | Internal Medicine | New York, NY | $558.58 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.5M
- Total Doctors 1
- Transactions 26
About LSZ102X
LSZ102X is a drug associated with $4.5M in payments to 1 healthcare providers, recorded across 26 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $983,241 was paid across 6 transactions to 0 doctors.
The most common payment nature for LSZ102X is "Unspecified" ($4.5M, 100.0% of total).
LSZ102X is associated with 4 research studies, including "A PHASE I AND OR IB OPEN LABEL STUDY OF LSZ102 SINGLE AGENT AND LSZ102 IN COMBINATION WITH EITHER LEE011 LSZ102 PLUS LEE011 OR BYL719 LSZ102 PLUS BYL719 IN PATIENTS WITH ADVANCED OR METASTATIC ER PLUS BREAST CANCER WHO HAVE PROGRESSED AFTER ENDOCRINE THER" ($3.3M).